All articles tagged with #pharmaceutical industry
The upcoming JPMorgan Healthcare Conference will showcase industry updates on drug pipelines, M&A activity, and the impact of recent drug pricing deals, with a focus on managing patent expirations, obesity treatments, and potential new drug developments from major pharma companies like Bristol Myers Squibb, Merck, Novo Nordisk, and Eli Lilly.
Johnson & Johnson has reached an agreement with the US government to lower drug prices for Americans in exchange for tariff exemptions, participating in initiatives to make medicines more affordable and building new manufacturing facilities in the US as part of a broader investment plan.
Johnson & Johnson has reached an agreement with the U.S. government to lower drug prices for Americans in exchange for tariff exemptions, participating in discounted drug sales and expanding manufacturing investments in the U.S.
Drugmakers plan to raise prices on at least 350 medicines in the US for 2026, including vaccines and cancer treatments, despite pressure from the Trump administration to lower costs. While some drugs will see price cuts, overall prices are increasing, with companies like Pfizer and GSK citing the need to support innovation and cover costs. These hikes occur even as the US continues to pay significantly more for prescription drugs compared to other developed nations.
Johnson & Johnson has discontinued its experimental eczema medication after it failed to meet efficacy standards, ending its $1.25 billion investment in the drug.
The former head of Pfizer R&D expresses concern about the future of the biopharma industry, highlighting past optimism about a productivity surge driven by genomic advances and new drug modalities, but implying that these expectations may not have been realized as hoped.
Novartis is close to acquiring Avidity Biosciences for over $70 per share, in a deal potentially valued at around $6.8 billion, aiming to strengthen its portfolio amid a wave of biotech M&A and upcoming patent expirations.
The FDA announced the first nine recipients of the Commissioner’s National Priority Review vouchers, which expedite drug reviews for products aligned with national health priorities. Notably, EMD Serono received a voucher after agreeing to lower prices for its fertility drugs, including Pergoveris, in a move highlighted by President Trump. The program aims to incentivize companies to develop and provide access to important medications.
Drug stocks are rallying as President Trump's proposed 100% tariff on branded pharmaceutical imports mainly affects companies without U.S. manufacturing, leaving most Big Pharma and generics unaffected. The tariffs highlight supply chain vulnerabilities and long-term national security concerns, especially dependence on foreign countries like China for generics, but could also hinder biotech innovation and complicate import processes.
Pfizer's surprise deal with the Trump administration on drug pricing, including measures like not launching new drugs at higher U.S. prices than in other wealthy countries and selling drugs at discounted rates, has caught other pharmaceutical companies off guard and increased pressure for similar agreements, potentially influencing future drug pricing and industry dynamics.
President Trump is set to announce the launch of 'TrumpRx', a website for discounted drugs, and a deal with Pfizer to lower medication costs, amid ongoing efforts to reduce drug prices in the US through policies like the 'Most Favored Nation' rule and direct-to-consumer sales channels, despite industry opposition and legal challenges.
GSK's CEO Emma Walmsley will step down in December after nine years, with Luke Miels, the company's chief commercial officer, named as her successor to lead the company into its next growth phase and meet future sales targets amid a challenging economic environment.
Eli Lilly's CEO criticizes the UK as the 'worst country in Europe' for affordable drug prices, highlighting concerns over pharmaceutical pricing policies.
Pfizer's new weight-loss drug is struggling to gain a foothold in the highly competitive market, limiting its impact and highlighting the challenges faced by pharmaceutical companies in this crowded sector.
Pfizer is expanding into the obesity treatment market with a nearly $5 billion acquisition of development-stage drugmaker Metsera, aiming to enhance its pipeline amid rising demand for obesity therapies and potential price competition.